These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22554381)

  • 21. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
    Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
    Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Thoc1 ribonucleoprotein and prostate cancer progression.
    Chinnam M; Wang Y; Zhang X; Gold DL; Khoury T; Nikitin AY; Foster BA; Li Y; Bshara W; Morrison CD; Payne Ondracek RD; Mohler JL; Goodrich DW
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25296641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
    Long Q; Johnson BA; Osunkoya AO; Lai YH; Zhou W; Abramovitz M; Xia M; Bouzyk MB; Nam RK; Sugar L; Stanimirovic A; Williams DJ; Leyland-Jones BR; Seth AK; Petros JA; Moreno CS
    Am J Pathol; 2011 Jul; 179(1):46-54. PubMed ID: 21703393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
    Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy.
    Tomaszewski JJ; Chen YF; Bertolet M; Ristau BT; Woldemichael E; Nelson JB
    Urology; 2013 May; 81(5):992-6. PubMed ID: 23453649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
    Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
    J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Hashimoto T; Ohori M; Shimodaira K; Kaburaki N; Hirasawa Y; Satake N; Gondo T; Nakagami Y; Namiki K; Ohno Y
    Int J Urol; 2018 Jun; 25(6):561-567. PubMed ID: 29633374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
    Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
    Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.